Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms.
- Author:
Jing-ping GE
1
;
Jun GONG
;
Hong-qing MA
;
Wu WEI
;
Xue-jun SHANG
;
Zheng-yu ZHANG
;
Song XU
;
Dong WANG
;
Jian-ping GAO
Author Information
- Publication Type:Clinical Trial
- MeSH: Adrenergic alpha-Antagonists; therapeutic use; Aged; Humans; Male; Middle Aged; Naphthalenes; therapeutic use; Piperazines; therapeutic use; Prostatic Hyperplasia; complications; drug therapy; Urinary Bladder, Overactive; complications; drug therapy
- From: National Journal of Andrology 2008;14(10):927-930
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms.
METHODSFifty BPH patients with OAB symptoms were treated with naftopidil at the dose of 25 mg/d for 6 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores (IPSS), quality of life indexes (QOL), maximum urinary flow rates (Qmax) , average urinary flow rates (Qave), voiding volumes (VV), blood pressures (BP) and heart rates (HR) obtained before and after the treatment.
RESULTSAfter 6 weeks' medication, the 46 assessable cases showed an average decrease of 9.75 in IPSS (P < 0.01), 3.97 in voiding symptom score (P < 0.01), 5.78 in urinary storage symptom score (P < 0.01) and 1.95 in QOL (P < 0.01), and a mean increase of 4.29 ml/s in Qmax (P < 0.01), 3.75 ml/s in Qave (P < 0.01) and 55.12 ml/s in VV (P < 0.05). But no significant changes were observed in BP and HR. Only 1 patient (4.35%) experienced the adverse event of dizziness.
CONCLUSIONThe alphalA/D blocker naftopidil is both effective and safe in the treatment of BPH patients with OAB symptoms.
